FCPA Pharmaceutical Targets Lacked Adequate Overseas Third-Party Vetting

The Justice Department's industry-wide probe of pharmaceutical companies demonstrates the dangers in inadequate third-party due diligence.

Unlock unlimited access to all Global Investigations Review content